Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes
- PMID: 24795225
- DOI: 10.1016/j.vaccine.2014.04.062
Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes
Abstract
Influenza A viruses drift and shift, emerging as antigenically distinct strains that lead to epidemics and pandemics of varying severity. Even epitopes associated with broad cross-protection against different strains, such as the ectodomain of matrix protein 2 (M2e), mutate unpredictably. Vaccine protective efficacy is only ensured when the emerging virus lies within the vaccine's cross-protective domain, which is poorly defined in most situations. When virus emerges outside this domain it is essential to rapidly re-engineer the vaccine and hence re-center the cross-protective domain on the new virus. This approach of vaccine re-engineering in response to virus change is the cornerstone of the current influenza control system, based on annual prediction and/or pandemic reaction. This system could become more responsive, and perhaps preventative, if its speed could be improved. Here, we demonstrate vaccine efficacy of a rapidly manufacturable modular capsomere presenting the broadly cross-protecting M2e epitope from influenza. M2e inserted into a viral capsomere at the DNA level was expressed in Escherichia coli as a fusion protein (Wibowo et al., 2013). Immunization of mice with this modular capsomere adjuvanted with conventional aluminum hydroxide induced high (more than 10(5) endpoint titer) levels of M2e-specific antibodies that reduced disease severity and viral load in the lungs of challenged mice. The combination of rapid manufacturability of modular capsomere presented in this study, and the established cross-protective efficacy of M2e, allow rapid matching of vaccine to the circulating virus and hence rapid re-centering of the vaccine's cross-protective domain onto the virus. This approach synergizes the discussed benefits of broadly cross-protecting epitopes with rapid scale-up vaccine manufacture using microbial cell factories.
Keywords: Capsomere; E. coli; M2e; Rapid manufacture; Vaccine.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.Vaccine. 2015 Jun 26;33(29):3398-406. doi: 10.1016/j.vaccine.2015.04.073. Epub 2015 May 11. Vaccine. 2015. PMID: 25976545
-
Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.Vaccine. 2008 Jan 10;26(2):201-14. doi: 10.1016/j.vaccine.2007.10.062. Epub 2007 Nov 20. Vaccine. 2008. PMID: 18063235
-
Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.Arch Virol. 2010 Apr;155(4):535-44. doi: 10.1007/s00705-010-0621-4. Epub 2010 Feb 27. Arch Virol. 2010. PMID: 20195654
-
M2-based influenza vaccines: recent advances and clinical potential.Expert Rev Vaccines. 2017 Feb;16(2):123-136. doi: 10.1080/14760584.2017.1240041. Epub 2016 Oct 5. Expert Rev Vaccines. 2017. PMID: 27653543 Review.
-
Influenza A viruses: why focusing on M2e-based universal vaccines.Virus Genes. 2011 Feb;42(1):1-8. doi: 10.1007/s11262-010-0547-7. Epub 2010 Nov 17. Virus Genes. 2011. PMID: 21082230 Review.
Cited by
-
Synthetic biology for bioengineering virus-like particle vaccines.Biotechnol Bioeng. 2019 Apr;116(4):919-935. doi: 10.1002/bit.26890. Epub 2018 Dec 31. Biotechnol Bioeng. 2019. PMID: 30597533 Free PMC article. Review.
-
Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.Antiviral Res. 2017 May;141:62-72. doi: 10.1016/j.antiviral.2017.01.021. Epub 2017 Feb 2. Antiviral Res. 2017. PMID: 28161578 Free PMC article.
-
Comparative evaluation of integrated purification pathways for bacterial modular polyomavirus major capsid protein VP1 to produce virus-like particles using high throughput process technologies.J Chromatogr A. 2021 Feb 22;1639:461924. doi: 10.1016/j.chroma.2021.461924. Epub 2021 Jan 21. J Chromatogr A. 2021. PMID: 33545579 Free PMC article.
-
Design strategies to address the effect of hydrophobic epitope on stability and in vitro assembly of modular virus-like particle.Protein Sci. 2016 Aug;25(8):1507-16. doi: 10.1002/pro.2953. Epub 2016 Jun 13. Protein Sci. 2016. PMID: 27222486 Free PMC article.
-
Escherichia coli-derived virus-like particles in vaccine development.NPJ Vaccines. 2017 Feb 9;2:3. doi: 10.1038/s41541-017-0006-8. eCollection 2017. NPJ Vaccines. 2017. PMID: 29263864 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical